Baxter Healthcare and Australian Government announce $40 million investment towards strengthening sovereign supply of IV fluids

Sydney - 2025-03-05

Baxter Healthcare (Baxter), an innovative leader in infusion therapies and technologies and Australia’s only onshore manufacturer of IV fluids, and the Australian Government today announced a landmark $40 million investment toward the company’s expansion of its Australian IV fluids manufacturing facility in Old Toongabbie, Western Sydney.

During a visit to Baxter’s Australian headquarters in Old Toongabbie, Minister for Health and Aged Care, Mark Butler, announced the Government’s decision to commit $20 million towards the expansion of Baxter’s Australian IV fluids manufacturing facility. The investment will support bolstering domestic production capabilities and help build a more resilient supply of IV fluids for Australia.

“The Albanese Labor Government is building Australia’s future by ensuring that critical medicines and medical supplies are manufactured here in Australia, by Australians,” said Minister Butler.

“This is an extraordinary investment in IV fluid production. 

“It will ensure we have a future made in Australia with onshore production to shield the country from global supply shocks that we have seen recently and through COVID.

“Baxter Healthcare’s facility has been an important part of manufacturing in Western Sydney for 50 years, and this investment will help it expand to produce another 20 million IV fluid bags every year.

“It means more jobs, more bags of IV fluid, and less dependence on overseas production.”

Baxter is also committing $20 million to the expansion project. The investment to increase the total capacity of its IV manufacturing operations in Old Toongabbie continues the company’s proud history in Australia for more than 50 years and its ongoing actions to support manufacturing of IV and irrigation fluids.

Baxter’s vice president and general manager for Australia and New Zealand, Brendan Cummins, said the company was proud to partner with the Australian Government to invest in its IV manufacturing operations in Western Sydney.

“As Australia’s only onshore manufacturer of Australian-made IV fluids, Baxter is committed to building an even stronger and more resilient supply of IV fluids for Australia, while also supporting local jobs,” said Mr Cummins.

“Today’s announcement by the Australian Government and Baxter to invest $40 million into the expansion of our Australian IV manufacturing plant is the single largest investment in this site since opening its doors over 50 years ago.

“Our manufacturing plant here in Old Toongabbie, Western Sydney, is a cutting-edge facility, thanks to the local expertise of our employees. We are very proud of our entire Baxter team, who continuously step up to support local caregivers and patients right across Australia.

“We thank the Government for investing with Baxter to help meet future anticipated need for these critical medicines, and we look forward to working closely with them and our local customers as we embark on this landmark expansion of our Australian IV plant.”

About Baxter

Every day, millions of patients, caregivers and healthcare providers rely on Baxter’s leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxterhealthcare.com.au and follow us on LinkedIn.

Media Contact:

Michael Doyle, (+61) 400 900 659

[email protected]

Investor Contact:

Clare Trachtman, (224) 948-3020

###